This mutation occurs in fewer than 5% of CMML patients.34,35 While it does not automatically signal a progression to AML, its significance lies in its potential impact on therapeutic strategies (FLT3 inhibitors).36–40. This evidence concerns the gene FLT3 and chronic myelomonocytic leukemia.